Phase 3 pivotal program in hemodialysis patients expected to commence in Q4 2017

STAMFORD, Conn. , Oct. 04, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced

Data from Phase 2 chronic osteoarthritis pain study of Oral CR845 to be presented in poster session at PAINWeek STAMFORD, Conn. , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed

Conference call today at 4:30 p.m. ET

STAMFORD, Conn. , Aug. 03, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that

STAMFORD, Conn. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced

STAMFORD, Conn. , July 27, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that

Tablet strengths exhibiting appropriate plasma levels identified for potential use in general CKD-associated pruritus patients

- Statistically significant 39 percent reduction in mean joint pain score in hip patients at eight weeks with 5.0 mg dose - - 35 percent reduction in mean joint pain score for all patients at eight weeks with 5.0 mg dose - - All tablet strengths well tolerated over eight-week treatment period - -

Phase 3 safety extension trial underway